| Serial Number | 97074028 |
| Word Mark | A2 BIO |
| Filing Date | Thursday, October 14, 2021 |
| Status | 732 - THIRD EXTENSION - GRANTED |
| Status Date | Thursday, November 7, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, April 4, 2023 |
| Goods and Services | custom manufacturing of therapeutics, biotherapeutics, medicines, and pharmaceuticals; manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells, in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease |
| Description of Mark | The mark consists of a black square with white frame and black border containing "A2" in white text in the lower right quadrant, with the word BIO in black text appearing under the number 2 and breaking the black and white border. |
| Goods and Services | Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes |
| Pseudo Mark | A TWO BIO |
| NOT AVAILABLE | "BIO" |
| Goods and Services | medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeutics, biotherapeutics, medicines, pharmaceuticals; identification and development of, therapeutic targets for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of cancer, inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information relating to treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 3, 2021 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 3, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 3, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | A2 Biotherapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Agoura Hills, CA 91301 |
| Party Name | A2 Biotherapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Agoura Hills, CA 91301 |
| Event Date | Event Description |
| Monday, October 18, 2021 | NEW APPLICATION ENTERED |
| Wednesday, November 3, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, November 4, 2021 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Wednesday, July 13, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, July 13, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, July 13, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, July 20, 2022 | ASSIGNED TO EXAMINER |
| Friday, July 22, 2022 | NON-FINAL ACTION WRITTEN |
| Friday, July 22, 2022 | NON-FINAL ACTION E-MAILED |
| Friday, July 22, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, January 23, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, January 23, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 24, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Saturday, February 25, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 15, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 4, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 4, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 30, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Friday, November 17, 2023 | SOU TEAS EXTENSION RECEIVED |
| Friday, November 17, 2023 | SOU EXTENSION 1 FILED |
| Friday, November 17, 2023 | SOU EXTENSION 1 GRANTED |
| Tuesday, November 21, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, May 14, 2024 | SOU EXTENSION 2 GRANTED |
| Tuesday, May 14, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, May 14, 2024 | SOU EXTENSION 2 FILED |
| Wednesday, May 15, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, November 7, 2024 | SOU TEAS EXTENSION RECEIVED |
| Thursday, November 7, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, November 7, 2024 | SOU EXTENSION 3 FILED |
| Thursday, November 7, 2024 | SOU EXTENSION 3 GRANTED |